COVID-19 Tests & Assay kits

Correct diagnosis of the coronavirus SARS-CoV-2 is of paramount importance in fighting the pandemic caused by it. Therefore a large effort was put into quickly developing tests and assay kits for detection of SARS-CoV-2 in, for example, blood or swabs from patients with symptoms of COVID-19. These kits are mainly focused on either identifying the viral RNA by RT-PCR or finding antibodies against the viral membrane proteins. Several of these testing systems have acquired the CE-IVD certification immediately and are therefore suitable for in vitro diagnostics of patients. One of the highly anticipated tests is the rapid test, which is a chromatographic immunoassay that indicates the presence of primary and secondary infection based on the presence of IgG and IgM antibodies against SARS-CoV-2. Bio-Connect Diagnostics offers a number of different rapid tests (with and without CE-IVD mark) as well as PCR-based assays. Additionally, we offer a number of high-quality ELISA kits for detection of IgG antibodies against SARS-CoV-2 or the identification of viral antigen proteins in human plasma and serum. Our assays allow high-throughput testing of a large number of patient samples or sporadic checks on individuals.

We offer various SARS-CoV-2 detection kits, such as rapid tests, PCR kits, ELISA kits and kits for viral sample preparation, including the iLAMP Novel CoV19 iONEBIO FICS. If you want to order, please send your request to: orders(at)

Products by category

COVID-19 Tests & Assay kits »»
CE-IVD kits »»
Request FFP2 Face Masks »»

Products by supplier

Click on the logos and go directly to their products.

COVID-19 Tests & Assay kits

Cat. No.Product NameDescriptionSupplier
E-ELC-008Buffer for Rapid Test Development (02)Elabscience
E-ELC-009Chicken IgYElabscience
E-ELC-006Chicken IgY (with colloidal gold conjugated)Elabscience
E-ELC-RTD001COVID-19 IgG/IgM Rapid Test Development KitElabscience
E-ELC-RTD002COVID-19 IgG/IgM Rapid Test Development Kit (No colloidal gold conjugated)Elabscience
E-ELC-005Goat anti-chicken IgY polyclonalElabscience
CSB-E04489hHuman ACE2 ELISA KitCusabio
CSB-EL001827HUHuman APN ELISA KitCusabio
CSB-E12994hHuman CD147 ELISA KitCusabio
E-HD-C044Human Corona Virus Disease 2019 (COVID-19) IgG/IgM Lateral Flow Assay Kit (RUO)This kit is a rapid chromatographic immunoassay for the qualitative detection of IgG and IgM antibodies specific to COVID-19 in human whole blood, serum or plasma as an aid in the scientific research of primary and secondary COVID-19 infections.Elabscience
CSB-E13450hHuman CTSB ELISA KitCusabio
CSB-EL3325HUHuman Novel Coronavirus Nucleoprotein (SARS-CoV-2 N) IgG Antibody ELISA KitFor the qualitative determination of human novel coronavirus nucleoprotein (SARS-CoV-2 N) IgG antibody concentrations in serum, plasma.Cusabio
CSB-EL3326HUHuman Novel Coronavirus Nucleoprotein/Spike Glycoprotein S1 (SARS-CoV-2 N/S1) IgG Antibody ELISA KitFor the qualitative determination of human novel coronavirus nucleoprotein/spike glycoprotein S1 (SARS-CoV-2 N/S1) IgG antibody concentrations in serum, plasma.Cusabio
CSB-EL33241HUHuman Novel Coronavirus Spike Glycoprotein RBD (SARS-CoV-2 S RBD) IgG Antibody ELISA KitFor the qualitative determination of human novel coronavirus spike glycoprotein RBD (SARS-CoV-2 S RBD) IgG antibody concentrations in serum, plasma.Cusabio
E-ELC-003Mouse anti-human IgG monoclonalElabscience
E-ELC-004Mouse anti-human IgM monoclonalElabscience
E-ELC-001Recombinant SARS-CoV-2 N Protein (His Tag)Elabscience
E-ELC-002Recombinant SARS-CoV-2 N Protein (with colloidal gold conjugated)Elabscience
DEIA2020SARS-CoV-2 Antigen ELISA KitCreative Group
DEIASL019SARS-CoV-2 IgG ELISA KitCreative Group
DEIASL020SARS-CoV-2 IgM ELISA KitCreative Group

CE-IVD kits

Cat. No.Product NameDescriptionSupplier
iLAMP Novel-CoV19 Detection Kit
The iLAMP Novel-CoV19 Detection Kit is intended for the qualitative detection of nucleic acid from SARS-CoV-2 in upper respiratory specimens such as nasal swabs, nasopharyngeal swabs and oropharyngeal swabs from individuals suspected of COVID-19 by their healthcare provider.
P0180Aridia COVID-19 Real-Time PCR Test (CE-IVD)This test is designed for specific and qualitative detection of the novel coronavirus SARS-CoV-2, responsible for COVID-19, in oropharyngeal swabs, nasopharyngeal swabs or sputum specimens as an aid in the diagnosis of COVID-19 infections, alongside all available clinical and epidemiological data, patient history, and other laboratory test outcomes. The product is intended for use by healthcare professionals specifically trained in nucleic acid amplification techniques and in vitro diagnostic procedures.CTK Biotech
UNCOV-40COVID-19 IgG/IgM Rapid Test Kit (CE-IVD)This kit is a rapid chromatographic immunoassay for the qualitative detection of IgG and IgM antibodies to COVID-19 in human whole blood, serum or plasma as an aid in the diagnosis of primary and secondary COVID-19 infections.Elabscience
COV2/GP/100GeneProof SARS-CoV-2 PCR Kit (CE-IVD)The SARS-CoV-2 PCR kit is intended for detection of newly described pathogen SARS-CoV-2.GeneProof
GeneProof SARS-CoV-2 Screening PCR Kit (CE-IVD)
R0180COnSite COVID-19 IgG/IgM Rapid Test (CE-IVD)This test is a lateral flow immunoassay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies in human serum, plasma or whole blood. It is intended to be used by healthcare professionals as an aid in the diagnosis of infection with SARS-CoV-2 coronavirus. Any interpretation or use of this preliminary test result must also rely on other clinical findings as well as on the professional judgement of healthcare providers. Alternative test method(s) should be considered to confirm the test result obtained by this device.CTK Biotech
MP Rapid 2019-nCoV IgG/IgM Combo Test Card (CE-IVD)
This is a rapid immunochromatographic test designed for the qualitative determination of IgG and IgM antibodies to 2019 novel coronavirus (2019-nCoV, SARS-CoV-2) in human serum, plasma or whole blood. It is intended for professional use as a clinical diagnostic tool.
MP Biomedicals
SARS-CoV-2 IgM/IgG Antibody Assay Kit (Immunochromatography) (CE-IVD)
This product is used for qualitative detection of IgM and IgG antibodies of SARS-CoV-2 in human serum, plasma, whole blood or fingertip blood in vitro.

In the process of pathogenic microorganism infection, IgG and IgM are the most commonly used antibody markers of infectious diseases. IgM, as the first antibody in the process of infection, is usually used as a marker of acute infection. With the development of infection, IgM concentration gradually decreased and disappeared after the appearance of IgG. IgG usually exists in the body for a long time, even if the virus has been completely eliminated. Positive blood can be used as an indicator of infection and previous infection. Therefore, detecting SARS-CoV-2 IgM antibody and IgG antibody is of great clinical significance and is of great significance for effective control of the large-scale transmission of SARS-CoV-2.
SARS-CoV-2 Nucleic Acid Dual-Detection Kit (Real-Time PCR Method) (CE-IVD)
The product is used for clinical qualitative detection of SARS-CoV-2 nucleic acid in specimens such as throat swabs, nasal swabs, the extract of nasopharyngeal, sputum, the extract of respiratory tract, bronchial perfusate, alveolar lavage fluid, lung tissue, stool, urine, blood or serum.


  1. ACE2 is the receptor for SARS (SARS-CoV). Li, W. et al., EMBO J (2005)24:1634-1643
  2. ACE2 is the receptor for the new virus, SARS-CoV-2. Zhou P, et al. (March 2020). "A pneumonia outbreak associated with a new coronavirus of probable bat origin". Nature. 579 (7798): 270–273.
  3. SARS-CoV-2 binding to ACE2 on human cells with at least 10x higher affinity than SARS-CoV. Wrapp, D., et al. Science 13 Mar 2020. Vol. 367( 6483): 1260-1263
  4. Angiotensin receptor blockers have been proposed as tentative SARS-CoV-2 therapeutics. Gurwitz D (March 2020). "Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics". Drug Development Research
  5. ACE2 has been shown to have a protective effect against virus-induced lung injury. Imai Y, et al. (July 2005). "Angiotensin-converting enzyme 2 protects from severe acute lung failure". Nature. 436 (7047): 112–6.
  6. El-Tholoth, Mohamed; Bau, Haim H.; Song, Jinzhao (2020): A Single and Two-Stage, Closed-Tube, Molecular Test for the 2019 Novel Coronavirus (COVID-19) at Home, Clinic, and Points of Entry. ChemRxiv. Preprint.
  7. Favipiravir (T-705), a Broad Spectrum Inhibitor of Viral RNA Polymerase. Furuta Y, et al. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449-463.
  8. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. Agostini ML, et al. mBio. 2018 Mar 6;9(2).
  9. Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-nCoV) in vitro. Wang M, et al. Cell Res. 2020 Mar;30(3):269-271.
  10. Effect of Toll-Like Receptor 7 and 9 Targeted Therapy to Prevent the Development of Hepatocellular Carcinoma. Mohamed FE, et al. Liver Int. 2015 Mar;35(3):1063-76.
  11. in vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Yao X, et al. Clin Infect Dis. 2020 Mar 9. pii: ciaa237.
  12. Novel Small Molecule Inhibitors of TLR7 and TLR9: Mechanism of Action and Efficacy in vivo. Lamphier M, et al. Mol Pharmacol. 2014 Mar;85(3):429-40.
  13. The Origin, Transmission and Clinical Therapies on Coronavirus Disease 2019 (COVID-19) Outbreak - An Update on the Status. Guo, Y., et al. Mil Med Res. 2020 Mar 13;7(1):11.
  14. SARS Coronavirus Replicase Proteins in Pathogenesis. Graham RL, et al. Virus Res. 2008 Apr;133(1):88-100.
  15. Characterization of the Receptor-Binding Domain (RBD) of 2019 Novel Coronavirus: Implication for Development of RBD Protein as a Viral Attachment Inhibitor and Vaccine. Wanbo Tai, et al. Cell Mol Immunol. 2020 Mar 19.
  16. Coronaviruses: An Overview of Their Replication and Pathogenesis. Fehr AR, et al. Methods Mol Biol. 2015;1282:1-23.
  17. SARS and MERS: Recent Insights Into Emerging Coronaviruses. de Wit E, et al. Nat Rev Microbiol. 2016 Aug;14(8):523-34.

More COVID-19 reagents »»